Privi Speciality Chemicals Ltd
Privi Speciality Chemicals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
From Privi Speciality Chemicals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%.
- A healthy order booking position of 65-70% for calendar year 2025 supports this confidence.
- Product mix improvements and internal efficiency enhancements contribute to margin sustainability and growth.
- Expansion through capacity increases and debottlenecking will support volume growth over the next 1-2 years.
- New product development, including high-value specialty products and new flagship products, will add to growth.
- Geographical expansion into markets like India, Africa, South Asia, and China is expected to drive growth, with >20% growth anticipated from Indian and African markets.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Privi Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products.
- This capex includes increasing existing product capacities and setting up capacities for a few new products.
- New products under development will form the next phase of expansion, for which Environmental Clearances (EC) and permissions have already been applied.
- The capex will be funded through a mix of internal accruals and debt.
- No immediate fundraising like QIP is planned; however, it may be considered in the future based on requirements.
- The company is also exploring co-manufacturing arrangements with competitors, though details are confidential.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Privi Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a healthy order booking position with about 65% to 70% of orders already confirmed for calendar year 2025.
- Around 70% of the business is contracted, primarily with large multinational F&F and FMCG companies, following calendar-year contracts.
- The remaining 30% is mostly spot market sales and largely within the Indian market.
- Management is confident about achieving revenue growth guided for FY25 and maintaining strong margins due to secured raw materials aligned with production volumes.
- There is visibility and confidence for a good order book position for the next few quarters, supporting growth.
2 more points management made on order book & pipeline
Privi Speciality Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹722 Cr, net profit ₹94 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Privi Speci.'s management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Laxmi Organic (Q3 FY25)
Specialty business pipeline remains strong with 11+ products, 60% fluoro-heavy, 40% other derivatives; focus on commercialization and capex for growth (Page…
- Tata Chemicals (Q3 FY25)
. Key concall takeaways from Tata Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Rain Industries (Q3 FY25)
. Key concall takeaways from Rain Industries's Q3 FY25 earnings call — and how it ranks against sector peers.
- Archean Chemical (Q3 FY25)
. Key concall takeaways from Archean Chemical Industries Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Privi Speciality Chemicals Ltd Q3 FY25 results?
The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
What is Privi Speciality Chemicals Ltd share price analysis?
Privi Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 40.7 with a market cap of ₹14,250 Cr. Investors should review the full earnings analysis for detailed insights.
Is Privi Speciality Chemicals Ltd planning capital expenditure?
Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products.
Keep Privi Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.